Guizhou Bailing Group Pharmaceutical Co., Ltd. is a company that specializes in the research, manufacturing, and marketing of traditional Chinese medicines. These medicines come in various forms such as tablets, capsules, syrups, soft capsules, granules, pills, powder, sprays, creams, and injections. The company's products are primarily used for the treatment of cardiovascular and cerebrovascular diseases, cough, common cold, and fever. Established on March 25, 1999, the company is headquartered in Anshun, China.

Tags

Cardiovascular Diseases

Nervous System Diseases

Respiratory Diseases

Herbal medicine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	4
Infectious Diseases	3
Endocrinology and Metabolic Disease	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Herbal medicine	7
Small molecule drug	1

Top 5 Target	Count

HDACs(Histone deacetylase)	1

Drugs associated with Guizhou Bailing Group Pharmaceutical Co., Ltd.

Compound Solidago decurrens Spray

Target-

Mechanism-

Active Org.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Originator Org.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Active Indication

Common Cold [+3]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date12 Aug 2019

JinGan

Target-

Mechanism-

Active Org.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Originator Org.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Active Indication

Common Cold [+4]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date09 Sep 2005

KeSuTing

Target-

Mechanism-

Active Org.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Originator Org.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Active Indication

Common Cold

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date30 Nov 2002

Clinical Trials associated with Guizhou Bailing Group Pharmaceutical Co., Ltd.

CTR20222507 / RecruitingPhase 2

注射用甲磺酸普依司他治疗复发或难治弥漫大B细胞淋巴瘤（DLBCL）的有效性和安全性的开放性、多中心Ⅱ期临床研究

[Translation] An open, multicenter phase II clinical study on the efficacy and safety of prilocastat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

IIa 期研究目的主要目的进一步探索注射用甲磺酸普依司他治疗复发或难治弥漫大 B细胞淋巴瘤的安全有效剂量；探索性目的：探索注射用甲磺酸普依司他疗效相关的生物标志物。 IIb 期研究目的主要目的：评估注射用甲磺酸普依司他治疗复发或难治弥漫大 B 细胞淋巴瘤的客观缓解率（ORR）。次要目的： 1．评估注射用甲磺酸普依司他治疗复发或难治弥漫大 B 细胞淋巴瘤的至肿瘤缓解时间（TTR）、缓解持续时间（DOR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）； 2.评估注射用甲磺酸普依司他治疗复发或难治弥漫大 B 细胞淋巴瘤的安全性及耐受性。

[Translation]

Phase IIa study objectives Main objectives To further explore the safe and effective dose of prilocastat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma; Exploratory objectives: To explore biomarkers related to the efficacy of prilocastat mesylate for injection. Phase IIb study objectives Main objectives: To evaluate the objective response rate (ORR) of prilocastat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Secondary objectives: 1. To evaluate the time to tumor response (TTR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) of prilocastat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma; 2. To evaluate the safety and tolerability of prilocastat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Start Date18 Oct 2023

Sponsor / Collaborator

Guizhou Bailing Group Pharmaceutical Co., Ltd.

[+1]

CTR20221473 / RecruitingPhase 2

芍苓片治疗寻常型银屑病（血瘀证）患者的随机、双盲、安慰剂对照、多中心Ⅱ期临床试验

[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical trial of Shaoling Tablets in the treatment of patients with psoriasis vulgaris (blood stasis syndrome)

以安慰剂为对照，初步评价芍苓片治疗寻常型银屑病（血瘀证）患者的有效性和安全性，并探索芍苓片治疗寻常型银屑病（血瘀证）患者的合理剂量，为Ⅲ期临床试验提供依据。

[Translation]

Using placebo as a control, this study preliminarily evaluated the efficacy and safety of Shaoling Tablets in the treatment of patients with psoriasis vulgaris (blood stasis syndrome), and explored the reasonable dosage of Shaoling Tablets in the treatment of patients with psoriasis vulgaris (blood stasis syndrome), providing a basis for Phase III clinical trials.

Start Date26 Sep 2023

Sponsor / Collaborator

Guizhou Bailing Group Pharmaceutical Co., Ltd.

NCT05366231 / CompletedPhase 4

A Randomized, Open-label, Positive Drug Parallel Controlled Clinical Trial of Kesuting Syrup in the Treatment of COVID-19 (Light)

This trial is an exploratory study, aiming to explore the preliminary efficacy and safety of Kesuting Syrup in the treatment of novel coronavirus pneumonia. It is planned to include a total of 200 cases. Kesuting Syrup test group: Lianhua Qingwen Granules control group = 1:1, each 100 cases in each group.

Start Date08 May 2022

Sponsor / Collaborator

Guizhou Bailing Group Pharmaceutical Co., Ltd.

100 Clinical Results associated with Guizhou Bailing Group Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with Guizhou Bailing Group Pharmaceutical Co., Ltd.

Literatures (Medical) associated with Guizhou Bailing Group Pharmaceutical Co., Ltd.

17 Jun 2024·Natural Product Research

Antiviral activity and active components of the leaves from Sabia parviflora Wall. ex Roxb

Article

Author: Pang, Yuxin ; Xiao, Junwei ; Xie, Shouxia ; Li, Sumei ; Yang, Xin ; Pan, Bowen ; Tang, Tingting ; Yang, Jian ; Xiao, Jinxin ; Zhou, Yongqiang ; Wei, Ying ; Zhou, Ying ; Wu, Guihui

Sabia parviflora (SP, "xiao hua qing feng teng" in Chinese) was recorded as an important ethnic medicine to be used for treating viral hepatitis. The antiviral activity of four SP extracts and potent antiviral compounds evaluated with cathepsin L protease (Cat L PR) and HIV-1 protease (HIV-1 PR). UPLC-HRMS was used for identifying the bioactive components. In addition, the possible inhibitory mechanism of the identified compounds on viral protease was further discussed by molecular docking. As a result, four extracts of SP exhibited inhibitory activity of HIV-1 PR and Cat L PR with IC₅₀ range from 0.015 to 0.80 mg/mL. Meanwhile, six compounds inhibited HIV-1 PR with IC₅₀ range from 0.032 to 0.80 mg/mL. Moreover, procyanidin B2 had good affinity for HIV-1 PR and CatL PR protein, respectively. These findings suggest S. parviflora leaves can be used for treating HIV and procyanidin B2 may play a role in antiviral protease.

01 Jan 2024·Clinical Immunology

Huanglian Jiedu Wan intervened with “Shi-Re Shanghuo” syndrome through regulating immune balance mediated by biomarker succinate

Article

Author: Zhao, Haiyu ; Wang, Hongjie ; Yang, Jiaying ; Zhou, Yanyan ; Si, Nan ; Chen, Yunqin ; Song, Jianfang ; Luo, Keke ; Qin, Guangyuan ; Zhang, Yan ; Li, Xing ; Wang, Mengxiao ; Wei, Xiaolu ; Xia, Wen ; Bian, Baolin ; Wang, Linna ; Tian, Mengyao

With increasing stress in daily life and work, subhealth conditions induced by "Shi-Re Shanghuo" syndrome was gradually universal. "Huanglian Jiedu Wan" (HLJDW) was the first new syndrome Chinese medicine approved for the treatment of "Shi-Re Shanghuo" with promising clinical efficacy. Preliminary small-sample clinical studies have identified some notable biomarkers (succinate, 4-hydroxynonenal, etc.). However, the correlation and underlying mechanism between these biomarkers of HLJDW intervention on "Shi-Re Shanghuo" syndrome remained ambiguous. Therefore, this study was designed as a randomized, double-blind, multicenter, placebo-controlled Phase II clinical trial, employing integrated analysis techniques such as non-targeted and targeted metabolomics, salivary microbiota, proteomics, parallel peaction monitoring, molecular docking and surface plasmon resonance (SPR). The results of the correlation analysis indicated that HLJDW could mediate the balance between inflammation and immunity through succinate produced via host and microbial source to intervene "Shi-Re Shanghuo" syndrome. Further through the HIF1α/MMP9 pathway, succinate regulated downstream arachidonic acid metabolism, particularly the lipid peroxidation product 4-hydroxynonenal. Finally, an animal model of recurrent oral ulcers induced by "Shi-Re Shang Huo" was established and HLJDW was used for intervention, key essential indicators (succinate, glutamine, 4-hydroxynonenal, arachidonic acid metabolism) essential in the potential pathway HIF1α/MMP9 discovered in clinical practice were validated. The results were found to be consistent with our clinical findings. Taken together, succinate was observed as an important signal that triggered immune responses, which might serve as a key regulatory metabolic switch or marker of "Shi-Re Shanghuo" syndrome treated with HLJDW.

01 Dec 2015·BMC Complementary and Alternative Medicine

Prevention of atherosclerosis by Yindan Xinnaotong capsule combined with swimming in rats

Article

Author: Yin, Xiaojie ; Wang, Jianlu ; Wang, Lan ; Cheng, Long ; Yang, Hongjun ; Liang, Rixin ; You, Yun ; Gao, Shuangrong ; Wang, Wandan ; Liao, Fulong ; Gong, Leilei ; Xu, Haiyu

BACKGROUNDYindan Xinnaotong capsule has been used for treating cardio-cerebrovascular diseases for several decades in China. Exercise training can protect against the development of atherosclerosis. The aim of the present study is to evaluate the joint effect of YXC and exercise on atherosclerosis in rats.METHODSA combined method involving low shear stress and a high-fat diet was used to establish the atherosclerosis model in rats. Partial ligation of the left common carotid artery was performed, and then the rats were divided into 9 treatment groups according to a 3 × 3 factorial design with two factors and three levels for each factor, swimming of 0, 0.5, 1 h daily and YXC administration of 0, 1, 2 g/kg p.o. daily. Next the interventions of swimming and YXC were executed for 8 weeks. After that, blood samples were collected to determine blood viscosity, plasma viscosity, haematocrit (HCT), fibrinogen (FIB), blood lipid profile (including total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG) and high-density lipoprotein-cholesterol (HDL-C)), nitric oxide (NO), 6-keto- prostaglandin (PG) F1α, endothelin (ET) and thromboxane (TX) B2. The common carotid arteries of the rats were harvested to examine pathological changes, wall thickness and circumference, and the expression of SM22αwas assayed via immune-histochemistry.RESULTSThe early pathological changes were observed. The joint effects of YXC and swimming showed significant changes in the examined parameters: (1) decreases in plasma viscosity, blood viscosity and FIB; (2) increases in NO and 6-keto-PGF1α; (3) decreases in ET and TXB2; and (4) decreases in LDL-C and TG. The combination of 2 g/kg YXC and 1 h of swimming led to synergistic decreases in LDL-C and TG. The interactive effect between YXC and swimming was obvious in decreasing wall thickness. Swimming alone was able to up-regulate the expression of SM22α.CONCLUSIONSIn conclusion, this study indicates that the combination of YXC and swimming may prevent atherosclerosis through a synergistic effect between YXC and swimming in improving blood circulation, hemorheological parameters, blood lipids levels and the vascular endothelium in rats. The vascular remodeling may be contributed to the prevention effects on AS by up-regulating SM22α.

100 Deals associated with Guizhou Bailing Group Pharmaceutical Co., Ltd.

100 Translational Medicine associated with Guizhou Bailing Group Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Phase 3 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Compound Solidago decurrens Spray	Stomatodysodia More	Approved
YinDanXinNaoTong	Angina Pectoris More	Approved
JinGan	Nasal Obstruction More	Approved
KeSuTing	Common Cold More	Approved
TangNing TongLuo Tablets	Diabetic Retinopathy More	Phase 3

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis